New Data on Resistance to DAAs and Implications for Therapy.2015

Nezam H. Afdhal, MD, FRCPIProfessor of MedicineHarvard Medical SchoolBeth Israel Deaconess Medical CenterBoston, Massachusetts

HCV Alert: New Data on Resistance to DAAs and Implications for Therapy

This activity is supported by an independent educational grant from Janssen Therapeutics.

clinicaloptions.com/hepatitisHCV Alert: New Data on Resistance to DAAs and Implications for Therapy

About These Slides Users are encouraged to use these slides in their own

noncommercial presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent

These slides may not be published or posted online without permission from Clinical Care Options (email [email protected])

DisclaimerThe materials published on the Clinical Care Options Web site reflect the views of the authors of the CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.


Faculty

Program Chair

Nezam H. Afdhal, MD, FRCPIProfessor of Medicine Harvard Medical SchoolBeth Israel Deaconess Medical CenterBoston, Massachusetts


FacultyJordan J. Feld, MD, MPHAssociate Professor of Medicine University of TorontoHepatologistToronto Centre for Liver DiseaseSandra Rotman Centre for Global HealthToronto, Canada

Norah Terrault, MD, MPHProfessor of Medicine and Surgery Director, Viral Hepatitis CenterDivision of GastroenterologyUniversity of California, San FranciscoSan Francisco, California

Mark S. Sulkowski, MDProfessor of MedicineMedical Director, Viral Hepatitis CenterDivisions of Infectious Diseases and Gastroenterology/HepatologyJohns Hopkins University School of MedicineBaltimore, Maryland


Faculty Disclosures

Nezam Afdhal, MD, FRCPI, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, and Vertex; has received consulting fees from AbbVie, Achillion, Catabasis, Cocrystal, Echosens, Gilead Sciences, GlaxoSmithKline, Janssen, Ligand, Merck, Roivant, Sandhill Scientific, and Spring Bank; and has stock options with Spring Bank.

Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Theravance and funds for research support from AbbVie, Boehringer Ingelheim, Gilead Sciences, Janssen, Merck, and Santaris.


Faculty Disclosures

Mark S. Sulkowski, MD, has disclosed that he has received consulting fees from AbbVie, Achillion, Bristol‐Myers Squibb, Gilead Sciences, Janssen, and Merck; and funds for research support (paid to his institution) from AbbVie, Bristol‐Myers Squibb, Gilead Sciences, Janssen, and Merck.

Norah Terrault, MD, MPH, has disclosed that she has received funds for research support from AbbVie, Biotest, Eisai, Gilead Sciences, Novartis, and Vertex and consulting fees from Achillion, Biotest, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Merck.


Virologic Barriers to Resistance

Genetic barrierNumber and type of nucleotide changes required for a virus to acquire resistance to an antiviral regimen[1]

Viral fitnessRelative capacity of a viralvariant to replicate in a given environment

1. Rong L, et al. Sci Transl Med. 2010;2:30ra32. 2. Le Pogam S et al. J Virol. 2006;80:6146-6154. 3. Le Pogam S, et al. J Infect Dis. 2010;202:1510-1519

Fitness of Polymerase Inhibitor Mutants[2,3]

Wild

Typ

e

L419

M

M42

3T

I482

LL4

19M

/M42

3T

S282

T

1

.75

.5

.25

0

% F

itnes

s


Resistant Variants Are Present Before and Can Be Selected During Treatment HCV is a mixture of related but distinct populations of virions in each pt[1]

Most resistant variants are unfit and may be undetectable prior to therapy[2,3]

1. Pawlotsky JM. Clin Liver Dis. 2003;7:45-66. 2. Kuntzen T, et al. Hepatology. 2008;48:1769-1778. 3. Bartels DJ, et al. J Infect Dis. 2008;198:800-807. Image reproduced and adapted with permission from Forum for Collaborative HIV Research. www.hivforum.org

Antiviral therapy eliminates sensitive variants Resistant variants expand

Sensitive virusResistant virus

Antiviral therapy


HCV NS3/4A Protease Resistance

Lenz O, et al. Antimicrob Agents Chemother. 2010;54:1878-1887. Reproduced with permission from American Society for Microbiology. doi:10.1128/AAC.01452-09 Copyright © 2010, American Society for Microbiology. All Rights Reserved.

Q80R155

D168

A156

F43


Naive Exp’d 1a + Q80K

1a no Q80K

All pts

97

Impact of Treatment Exp, Q80K Depends on Cirrhosis (12 Wks’ SMV + SOF in GT1)

1. Kwo P, et al. EASL 2015. Abstract LP14. 2. Lawitz E, et al. EASL 2015. Abstract LP04.

SVR

12 (%

)

100

80

60

40

20

0

97 95 96

112/115

38/40

44/46

68/70n/N =

Naive Exp’d

Treatment History

HCV GT

1a + Q80K

1a no Q80K

97

150/155

All pts

8879

74

92

44/50

42/53

25/34

35/38

Treatment History

HCV GT

83

86/103

No Cirrhosis (OPTIMIST-1[1]) Cirrhosis (OPTIMIST-2[2])

100

80

60

40

20

0n/N =


OPTIMIST-2: Resistance Analysis in GT1 Cirrhotics in Whom SMV + SOF Failed Treatment-emergent NS3 mutations detected in 79%

(11/14) of evaluable pts who did not achieve SVR12

– Observed at position 168, R155K, or combinations

NS5B polymorphism S282T not detected at baseline or at time of treatment failure

No NS3 baseline polymorphisms observed aside from Q80K

Lawitz E, et al. EASL 2015. Abstract LP04.


AASLD/IDSA Guidance for Resistance Testing When Considering SMV + SOF In pts with both genotype 1a HCV infection and

compensated cirrhosis, if considering SMV + SOF, test for Q80K polymorphism

– If Q80K variant is present, consider a regimen other than SMV + SOF

Applies to treatment-naive and treatment-experienced pts

Q80K testing not required for:

– Pts with genotype 1b HCV infection

– Pts without cirrhosis

– Pts in whom you are considering other DAAsAASLD/IDSA/IAS-USA. HCV Guidance.


ION-2: DAAs Effective Against NS3 RAVs After Boceprevir or Telaprevir

Virologic failure: 1 breakthrough in 24-wk LDV/SOF + RBV due to nonadherence; 11 relapses (7 in 12-wk LDV/SOF, 4 in 12-wk LDV/SOF + RBV)

14% of pts had NS5A RAVs at baseline; 89% of these achieved SVR12; 71% of pts had NS3 RAVs at baseline; 98% of these achieved SVR12

40/43

62/66

45/47

62/64

58/58

49/50

58/59

51/51

12 Wks 24 WksLDV/SOF + RBV LDV/SOF + RBVLDV/SOF LDV/SOF

SVR

12 (%

)

100

80

60

40

20

0

93 94 96 97 1009898100

Failure of pegIFN/RBV

Failure of PI

Treatment History

Afdhal N, et al. N Engl J Med. 2014;370:1483-1493.


Fold-Change in EC50 Genotype 1a Genotype 1bPosition M28T Q30R L31M/V Y93H/N L31V Y93H/NFDA approvedDaclatasvir[1,3] > 100 x > 1000 x > 100 x > 1000 x < 10 x < 100 x

Ledipasvir[1] 20 x > 100 x > 100 x > 1000 x > 1000 x/?

Ombitasvir[2] > 1000 x > 100 x< 3 x

> 10,000 x < 10 x < 100 x> 100 x

1. Cheng G, et al. EASL 2012. Abstract 1172. 2. Krishnan P, et al. Antimicrob Agents Chemother. 2015;59:979-987. 3. Yang G, et al. EASL 2013. Abstract 1199. 4. Ng T, et al. CROI 2014. Abstract 639.

Resistance Analysis of Select NS5A Inhibitors in Genotype 1 HCV

> 100 x 3 to 100 x < 3 x


NS5A RAVS with < 100 x resistance

Sarrazin C. AASLD 2014. Abstract 1926.

Impact of Duration of LDV/SOF on SVR12 in Pts With Baseline NS5A Resistance

10080

60

40

20

0

10080

60

40

20

0

100 83 95

10065

95 100 100 99

100 92 96100 96 97

12/12

24/29

184/193

110/116

11/17

5/5

27/27

44/46

362/373

95/96

6/6

7/7

8/8

24/25

174/183

8 Wks 12 Wks 24 Wks

Treatment Naive

Treatment Experienced

12 Wks 24 Wks

SVR

12 (%

)SV

R12

(%)

n/N =

n/N =

NS5A RAVS with > 100 x resistance No NS5A RAVs


Durability of Treatment-Emergent NS5A RAVs After Virologic Failure Study of pts not achieving SVR after receiving LDV without SOF

NS5A RAVs persisted in majority of pts for 96 wks

100

80

60

40

20

0VF Baseline FU-12 FU-24 FU-48 FU-96

98 100 98 100 9586

Pts

With

NS5

A R

AVs

(%)

Registry Study

62/63

58/58

42/43

45/45

52/55

50/58

n/N =

Dvory-Sobol H, et al. EASL 2015. Abstract O059.


Pooled Analysis: RAV Persistence After Failure of PTV/RTV-, OMV-, DSV-Based Tx

100

80

60

40

20

0

PTV-Containing Regimens

Any D168 R155K

46

9

38

77

29

4

100

80

60

40

20

0

OMV-Containing Regimens

Any M28V/T Q30E/K/R

97 96 97 10093 89

100

80

60

40

20

0

DSV-Containing Regimens

Any S556G

75

90

57

77

Follow-up Wk 24 Follow-up Wk 48

n/N = n/N = n/N = 31/67 5/57

21/55 2/53

10/13 2/7

68/70

32/33

38/41

49/51

21/21

25/28

33/44

27/30

20/35

17/22

RA

Vs (%

)

RA

Vs (%

)

RA

Vs (%

)

NS3/4A Position NS5A Position NS5B Position

Krishnan P. EASL 2015. Abstract O057.


92100

91

0/1200/218

AVIATOR: No Impact of Baseline RAVs in GT1a Pts Treated With OMV/PTV/RTV + DSV Treatment naive pts or null responders to previous pegIFN/RBV

All differences in SVR24 with vs without baseline RAVs were nonsignificant

Krishnan P, et al. Antimicrob Agents Chemother. 2015;59:5445-5454.

100

80

60

40

20

0

NS3 RAVs

Q80K D168

88 94

0

92100

80

60

40

20

0

NS5A RAVs

M28V/T Q30R L31V

86 92

100

91100

80

60

40

20

0

NS5B RAVs

S556G C316Y

100

50

93

With RAV

n/N = n/N = n/N = 12/14

3/3

1/1

192/209

201/220

203/222

7/7

1/2

220/239

226/244

Y93C/N/H

8092

4/5

200/218

78/89

122/130

SVR

24 (%

)

SVR

24 (%

)

SVR

24 (%

)

Without RAV


Wyles DL, et al. Hepatology. 2015;61:1793-1797.

GT1 HCV with previous SOF

failure (29% cirrhotic)*

(N = 51)

LDV/SOF + RBV

12 Wks

*25 pts (49%) were previously treated with SOF + pegIFN/RBV, 21 (41%) with SOF ± RBV, 5 (10%) with SOF placebo plus pegIFN/RBV or GS-0938 monotherapy, 1 (2%) with SOF monotherapy.†1 pt who relapsed found to have GT3a HCV infection and enrolled in error.

SVR12, %

98†

LDV/SOF + RBV in GT 1 HCV Pts With Previous Failure on Sofosbuvir Regimens Phase II trial


GT1 HCV–infected pts with and without cirrhosis previously treated with 8 or 12 wks of LDV/SOF ± RBV or LDV/SOF + GS-966

24 Wks of LDV/SOF Retreatment After Failure of 8-12 Wks of LDV/SOF-Based Tx

Lawitz E, et al. EASL 2015. Abstract O005.

Previous Tx Duration

100

80

60

40

20

0

SVR

12 (%

)

All No Yes

71 6874

15/22

14/19

No Yes8 Wks 12 WksCirrhosis BL NS5A RAVs

80

46

60

100

24/30

5/11

11/11

18/30n/N =

29/41


24 Wks of LDV/SOF After Failure of LDV/ SOF-Based Tx: Effect of Baseline RAVs

NS5B variants emerged during retreatment in 33% of pts (4/12) with virologic failure

– S282T: n = 2; L159F: n = 1; S282T + L159F: n = 1Lawitz E, et al. EASL 2015. Abstract O005.

SVR12 by Baseline NS5A RAVs, n/N (%) LDV/SOF for 24 WksNumber of RAVs 0 11/11 (100) 1 11/16 (69) ≥ 2 7/14 (50)

Single NS5A RAV Q30R or M28T 5/5 (100) L31M 4/5 (80) Y93H/N 2/6 (33)


GT1 Pts With NS5A Failure: Who Needs Resistance Testing? If previous failure of any NS5A inhibitors (including DCV + SOF,

LDV/SOF, OMV/PTV/RTV + DSV) and minimal liver disease, deferral preferred pending further data

– If cirrhosis or other need for urgent treatment, test for NS3 and NS5A RAVs

Applies to genotype 1a and 1b HCV infection

NS3 and NS5A testing not required for:

– Previous failure of NS3/4A PIs (including simeprevir, boceprevir, telaprevir)

– Previous failure of NS5B inhibitors (sofosbuvir)

– Tx-naive pts (unless considering SMV + SOF in cirrhotic GT1a)AASLD/IDSA/IAS-USA. HCV Guidance.


Selecting Treatment Based on Resistance Testing Results If genotype 1a or 1b HCV infection and previous failure

with any NS5A inhibitors and cirrhotic or other need for urgent treatment:

AASLD/IDSA/IAS-USA. HCV Guidance.

RAV Testing Result Retreatment Regimen DurationNo NS5A RAVs Ledipasvir/sofosbuvir + ribavirin 24 wksNS5A but no NS3 RAVs Simeprevir + sofosbuvir + ribavirin 24 wksNS5A and NS3 RAVs Retreatment in a clinical trial setting


Is Ribavirin Required for Pts With Cirrhosis? Integrated analysis of > 500 pts with cirrhosis treated with LDV/SOF ± RBV

Treatment-experienced pts had previously received HCV PI

Although NS5A resistance not measured, RBV overcomes shorter treatment duration in patients with HCV cirrhosis and prior treatment failure

SVR12, % Total(N = 513)

Treatment Naive(n = 161)

Treatment Experienced(n = 352)

Overall 96 98 95

12 wks ± RBV 95 97 94

24 wks ± RBV 98 99 98Without RBV 95 96 95With RBV 97 99 9612 wks without RBV 92 96 9012 wks with RBV 96 98 9624 wks without RBV 98 97 9824 wks with RBV 100 100 100

Reddy KR, et al. Hepatology. 2015;62:79-86.


Is Ribavirin Required for Pts With Cirrhosis and NS5A RAVs? Integrated analysis of > 500 pts with cirrhosis treated with

LDV/SOF ± RBV

Treatment experienced patients had previously received HCV PI

SVR12, % (n/N)18 With NS5A RAVs Without NS5A RAVsOverall 91 (86/94) 98 (407/417)12 wks without RBV 88 (23/26) 95 (86/91)12 wks with RBV 94 (32/34) 97 (164/169)24 wks without RBV 85 (17/20) 100 (113/113)24 wks with RBV 100 (14/14) 100 (44/44)

Reddy KR, et al. Hepatology. 2015;62:79-86.


Personal Recommendations for Resistance in GT3 and GT4 HCV Infection Genotype 3

– Treatment failures on daclatasvir should be tested for NS5A RAVs

– BOSON: Adding pegIFN to SOF/RBV appears to help overcome virologic failure due to resistance in GT3[1]

– Improved SVR12 vs SOF/RBV alone in both treatment-naive and treatment-experienced pts, with or without cirrhosis

Genotype 4– Resistance testing should be performed if considering

retreatment after LDV/SOF failure

– Use SMV/SOF/RBV for NS5A RAVs1. Foster GR, et al. EASL 2015. Abstract LO5.


Summary Baseline RAVs (especially NS5A) are present in treatment-naive pts

Treatment-emergent RAVs (including multidrug-resistant RAVs) seen in treatment failure and in all DAA classes and rarely with SOF

NS3 RAVs have low replication efficacy and disappear over 9-18 mos

– If considering SMV + SOF: In treatment-naive and treatment-experienced pts with both genotype 1a HCV infection and compensated cirrhosis, ensure no Q80K

NS5A treatment-emergent RAVs persistent and a clinical challenge

– If failure with any NS5A inhibitors (including DCV + SOF, LDV/SOF, OMV/PTV/RTV + DSV), and treatment is urgent, test for NS3 and NS5A RAVs

– Use SMV + SOF + RBV if NS5A but no NS3 RAVs

– Use LDV/SOF + RBV if no NS5A RAVs

– Treat in clinical trial if both NS5A and NS3 RAVs present

Resistance testing may be of benefit in treatment failures

Go Online for More CCO Coverage of HCV Resistance!

Online CME-certified interactive text module with expert analysis of key data

CME-certified downloadable slides with slidenotes

clinicaloptions.com/hepatitis

http://www.clinicaloptions.com/hepatitis

New Data on Resistance to DAAs and Implications for Therapy.2015

Health & Medicine

Transcript of New Data on Resistance to DAAs and Implications for Therapy.2015